First human imaging data validate MT1-MMP BRC radiopharmaceutical potential; strategy outlined

BICYCLE THERAPEUTICS PLC

First human PET/CT data for gallium-68-labelled MT1-MMP BRC show tracer uptake in lung cancer primary and metastases consistent with FDG imaging.
Preclinical data demonstrate BRC biodistribution optimized to maintain high tumor uptake while significantly reducing kidney retention.
Company selects EphA2 as second BRC target; signs letter of intent with Eckert & Ziegler for isotope supply and manufacturing.
CEO Kevin Lee highlights strategy to pursue novel targets with first-in-class radiopharmaceuticals using Bicycle platform.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.